-transparent.png){kind=logo}
Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study. 1990
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
University of Western Ontario, London, Canada.
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.
Related Publications
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
February 1990,
Investigational new drugs,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
October 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
July 2006,
Investigational new drugs,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
October 1991,
Annals of oncology : official journal of the European Society for Medical Oncology,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
January 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
August 1986,
Cancer treatment reports,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
November 1986,
Cancer treatment reports,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
September 1988,
Investigational new drugs,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
January 1998,
Investigational new drugs,
J G Cairncross, and
E A Eisenhauer, and
D R Macdonald, and
M P Rathbone, and
M J Moore, and
C A Sawka, and
R E MacCormick, and
I G Kerr
October 1986,
Cancer treatment reports,
